Highline Wealth Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Highline Wealth Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$264	–	1100
2025 Q1	$264	Buy	+2	New	+$249	﹤0.01%	925

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highline Wealth Partners's ITCI Position: Q2 2025 in Review

Highline Wealth Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2 shares — an estimated $264 sold.

Highline Wealth Partners first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $264 in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Highline Wealth Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Highline Wealth Partners sold 2 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $264.
Highline Wealth Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Highline Wealth Partners's Intra-Cellular Therapies Inc. position peaked at $264 in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.